search button
Open Access

Elevated FKBP52 expression indicates a poor outcome in patients with breast cancer

  • Authors:
    • Chaoqun Hong
    • Ting Li
    • Fan Zhang
    • Xiao Wu
    • Xipeng Chen
    • Xiaojiang Cui
    • Guojun Zhang
    • Yukun Cui

  • View Affiliations

  • Published online on: August 25, 2017     https://doi.org/10.3892/ol.2017.6828
  • Pages: 5379-5385

  • Copyright: © Hong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The 52‑kDa FK506‑binding protein (FKBP52), a regulator of steroid hormone receptor signaling, is potentially involved in a variety of hormone‑dependent cancer types. The present study investigated the expression and clinical implications of FKBP52 in breast cancer. Immunohistochemistry was performed on samples from 145 breast cancer patients and on 66 unmatched breast non‑cancerous tissues (as controls) to determine the expression level of FKBP52. Publicly available microarray and RNA‑seq datasets used in the present study were downloaded from the European Bioinformatics Institute ArrayExpress. Kaplan‑Meier survival analysis was also performed. FKBP52 expression was moderately higher in the tumors than that in the non‑cancerous tissues, but this difference was not statistically significant (P=0.176). However, available microarray datasets exhibited a significant difference in FKBP52 mRNA levels between breast tumors and controls. In the 145 breast cancer patients, elevated FKBP52 expression was significantly associated with advanced Tumor‑Node‑Metastasis (TNM) stage (P=0.015), lymph node metastasis (P=0.015) and tumors with poor histological differentiation (P=0.047). FKBP52 expression was negatively associated with estrogen receptor expression (P=0.033), but positively associated with human epidermal growth factor receptor 2 expression (P=0.033). However, there was no association between FKBP52 and progesterone receptor expression. Survival analyses demonstrated that FKBP52 was indicative of a poor overall survival rate (P=0.026), which was consistent with the result of Kaplan‑Meier analysis, exhibiting a negative association between the mRNA of FKBP52 and overall survival (OS) (P=0.044). Other than for FKBP52 [hazard ratio (HR), 2.315; 95% confidence interval (CI), 1.077‑4.975; P=0.032], univariate analysis revealed that clinical stage exhibited a significant influence on the prognosis of the breast cancer patients (HR, 2.148; 95% CI, 1.011‑4.566; P=0.047). However, multivariate analysis revealed that only clinical stage, not FKBP52, was an independent prognostic factor (HR, 2.721; 95% CI, 1.169‑6.335; P=0.020). Patients were further classified according to their OS. Compared with the controls (3.94±2.992), FKBP52 expression in breast cancer patients with OS of ≤3 years (5.39±3.409; P=0.042) or OS of ≤5 years (5.88±3.473; P=0.005) was significantly increased, respectively. However, no significant difference in FKBP52 expression was observed between controls and individuals with an OS time of >3 years (4.84±3.769; P=0.109) or >5 years (5.32±3.372; P=0.090). Elevated FKBP52 expression may be involved in tumor progression and invasion, given its positive association with TNM stage and lymph node metastasis. Although it is not an independent predictor, FKBP52 has promise as a biological marker for estimating the progression of breast cancer.
View Figures
View References

Related Articles

Journal Cover

November-2017
Volume 14 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Hong C, Li T, Zhang F, Wu X, Chen X, Cui X, Zhang G and Cui Y: Elevated FKBP52 expression indicates a poor outcome in patients with breast cancer. Oncol Lett 14: 5379-5385, 2017.
APA
Hong, C., Li, T., Zhang, F., Wu, X., Chen, X., Cui, X. ... Cui, Y. (2017). Elevated FKBP52 expression indicates a poor outcome in patients with breast cancer. Oncology Letters, 14, 5379-5385. https://doi.org/10.3892/ol.2017.6828
MLA
Hong, C., Li, T., Zhang, F., Wu, X., Chen, X., Cui, X., Zhang, G., Cui, Y."Elevated FKBP52 expression indicates a poor outcome in patients with breast cancer". Oncology Letters 14.5 (2017): 5379-5385.
Chicago
Hong, C., Li, T., Zhang, F., Wu, X., Chen, X., Cui, X., Zhang, G., Cui, Y."Elevated FKBP52 expression indicates a poor outcome in patients with breast cancer". Oncology Letters 14, no. 5 (2017): 5379-5385. https://doi.org/10.3892/ol.2017.6828